Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Cancer Res. 2010 Dec 1;71(3):686–692. doi: 10.1158/0008-5472.CAN-10-2666

Figure 2.

Figure 2

The open two-compartment pharmacokinetic model used for our analysis. Luciferin is administered via IP injection and passes into the bloodstream with first-order kinetics (ka). Once in the bloodstream, luciferin can move into the tumor (rate constant kbt) or be eliminated from the body (rate constant kel). In the tumor, luciferin is passed back into the bloodstream (rate constant ktb) or it interacts with the luciferase expressed in the tumor resulting in photon emission.